INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Maravai LifeSciences Holdings, Inc- MRVI
NEW YORK, March 3, 2025 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Maravai LifeSciences Holdings, Inc (“Maravai” or the “Company”) (NASDAQ: MRVI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Maravai and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On February 25, 2025, Maravai announced that the Company is delaying its fourth quarter and full year 2024 earnings release and requires additional time to complete its year-end financial close process.
On this news, Maravai’s stock price fell $0.87 per share, or 21.7%, to close at $3.14 per share on February 25, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-maravai-lifesciences-holdings-inc–mrvi-302390724.html
SOURCE Pomerantz LLP
Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.